Glad we are on the same page, positive TGA news will be great for investor confidence. I've had a small position in this company since November 2020 and love the work they have achieved over the years. Little disappointing to see this TGA process go a little off track for them, but hey they paid the ultimate price by losing all those options. I've tried my best to compare them to some of the other similar products out there, and there seem to be a few that can put together some pretty significant accuracies for detection (but you really have to pay the price $500-$1000+). Rhythm's accuracy results to me seem to be impressive but they are not the best, but what does seem to be on their side is that it is cheap?
I guess what I'm trying to piece together is whether this very low price point they've (kind of) set is exactly what they need to be able to scale this product into something big. Considering it's still more accurate than the current market standard FIT test, and cheaper too if they then did get TGA approval I don't see how they aren't able to strike some sort of deal? And what that deal might look like is a big part of the equation and difficult for me to understand.
I'd like to hear what others see on this and how important you think the pricing is here. I loved the discussion on sensitivity and specificity in the different stages for all these products, which I'm also convinced can play a pretty big role in the success of each of them. But you would think people will want very accurate but also very affordable, whoever gets that right is likely a winner?? But there seems to be a bit of a balance that needs to be found between the two. What's better? That it's cheaper but a bit less accurate or that it's more accurate but more expensive? Well, I guess it depends on the situation. If you are trying to make a product that is to screen as many people as possible and hopefully increase the screening participation rates, the product needs to be cheap to make and hopefully free for users. Are there other products that I'm missing that are as cheap as ColoSTAT and more accurate than current market standards?
- Forums
- ASX - By Stock
- Ann: MST Access Financial Diagnostics Presentation
RHY
rhythm biosciences limited
Add to My Watchlist
15.4%
!
6.0¢

Glad we are on the same page, positive TGA news will be great...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
6.0¢ |
Change
0.008(15.4%) |
Mkt cap ! $17.04M |
Open | High | Low | Value | Volume |
5.2¢ | 6.0¢ | 5.2¢ | $21.32K | 381.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 198929 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.0¢ | 248871 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 198929 | 0.056 |
1 | 98789 | 0.055 |
1 | 20507 | 0.054 |
1 | 97 | 0.051 |
6 | 547611 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.060 | 248871 | 4 |
0.062 | 43127 | 1 |
0.065 | 5377 | 1 |
0.075 | 88927 | 1 |
0.080 | 38871 | 2 |
Last trade - 15.42pm 04/07/2025 (20 minute delay) ? |
Featured News
RHY (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online